본문 바로가기

Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials

문서 유형
연구출판물 · 학술지 논문
등재
ESCIScopus
저널 순위
JCR Q1Scopus Q2
저널
KIDNEY MEDICINE6(8) · 2024
피인용
Scopus 27
FWCI (Scopus)
3.55
JCR IF
JCR 2023 3.2
ISSN
2590-0595

저자

  1. Dixon, Bradley P.제1저자교신저자Renal Section, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO
  2. Kavanagh, DavidNational Renal Complement Therapeutics Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom
  3. Aris, Alvaro Domingo MadridChildren's Nephrology and Renal Transplantation Service, Children's Maternity Hospital Sant Joan de Deu, University of Barcelona, Barcelona, Spain
  4. Adams, BrigitteDepartment of Pediatric Nephrology, Children's Hospital Queen Fabiola, Universite libre de Bruxelles, Brussels, Belgium
  5. Kang, Hee GyungDivision of Pediatric Nephrology, Department of Pediatrics, Seoul National University College of Medicine, Seoul, Republic of Korea
  6. Wang, EdwardAlexion, AstraZeneca Rare Disease, Boston, MA
  7. Garlo, KatherineAlexion, AstraZeneca Rare Disease, Boston, MA
  8. Ogawa, MasayoAlexion, AstraZeneca Rare Disease, Boston, MA
  9. Amancha, PraveenAlexion, AstraZeneca Rare Disease, Boston, MA
  10. Chakravarty, SourishAlexion, AstraZeneca Rare Disease, Boston, MA
  11. Heyne, NilsSection of Nephrology and Hypertension, Department of Internal Medicine IV, University Hospital Tubingen, Tubingen, Germany
  12. 김성헌Department of Pediatrics, Pusan National University Children's Hospital, Yangsan, Republic of Korea
  13. Cataland, SperoDivision of Hematology, The Ohio State University Medical Center, Columbus, OH
  14. Yoon, Sung-SooDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea
  15. Miyakawa, YoshitakaDepartment of Hematology, Saitama Medical University, Saitama, Japan
  16. Luque, YosuRenal Intensive Care Unit, Nephrology Department, Tenon Hospital, Assistance Publique-Hopitaux de Paris, Sorbonne Universite, Paris, France
  17. Muff-Luett, MelissaDivision of Pediatric Nephrology, University of Nebraska Medical Center, Omaha, NE
  18. Tanaka, KazukiDepartment of Nephrology, Aichi Children's Health and Medical Center, Aichi, Japan
  19. Greenbaum, Larry A.Division of Pediatric Nephrology, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA

초록

Rationale & Objective: Atypical hemolytic uremic syndrome (aHUS) is a rare form of thrombotic microangiopathy (TMA) caused by complement dysregulation. Ravulizumab is a C5i approved for the treatment of aHUS. This analysis assessed long-term outcomes of ravulizumab in adults and pediatric patients with aHUS. Study Design: This analysis reports 2-year data from 2 phase 3, single-arm studies. Setting & Participants: One study included C5i-naïve adults (NCT02949128), and the other included 2 cohorts of pediatric patients (C5i-naïve and those who switched to ravulizumab from eculizumab [pediatric switch patients]; NCT03131219). Exposure: Patients received intravenous ravulizumab every 4-8 weeks, with the dose depending on body weight. Outcomes: The primary endpoint in the studies of C5i-naïve patients was complete TMA response, which consisted of platelet count normalization, lactate dehydrogenase normalization, and ≥25% improvement in serum creatinine concentrations from baseline, at 2 consecutive assessments ≥4 weeks apart. Analytical Approach: All analyses used descriptive statistics. No formal statistical comparisons were performed. Results: In total, 86 and 92 patients were included in efficacy and safety analyses, respectively. Complete TMA response rates over 2 years were 61% and 90% in C5i-naïve adults and pediatric patients, respectively. The median increase in estimated glomerular filtration rate from baseline was maintained over 2 years in C5i-naïve adults (35 mL/min/1.73 m2) and pediatric patients (82.5 mL/min/1.73 m2). Most adverse events and serious adverse events occurred during the first 26 weeks. No meningococcal infections were reported. Improvement in the Functional Assessment of Chronic Illness Therapy – Fatigue score achieved by 26 weeks was maintained over 2 years. Limitations: Limitations were the small sample of pediatric switch patients and limited availability of genetic data. Conclusions: Long-term treatment with ravulizumab is well tolerated and associated with improved hematologic and renal parameters and quality of life in adults and pediatric patients with aHUS. Plain-Language Summary: This research tested a drug called ravulizumab for the treatment of atypical hemolytic uremic syndrome (aHUS). aHUS is a rare disease that causes clots in tiny blood vessels. This can damage the kidneys and other organs. We analyzed data from 2 clinical trials in which children and adults with aHUS received ravulizumab through a tube placed in a vein (intravenous line). They received ravulizumab every 4-8 weeks depending on their weight. We found that treating patients for 2 years with ravulizumab was associated with improved blood health, kidney function, and quality of life and was well tolerated. These results support ravulizumab as a long-term treatment for people with aHUS.

키워드

Adultatypical hemolytic uremic syndromecomplement C5 inhibitorefficacyhematologynephrologypediatricravulizumabsafetythrombotic microangiopathy

식별자

Scopus EID
2-s2.0-85198062971